New Research Shows Increase in Link between Actos, Bladder Cancer - 2012-06-04

dangerous drugs

A new study shows an increase in the likelihood that a popular diabetes drug may lead to bladder cancer as an unfortunate result of taking the drug. Langdon & Emison has litigated a diverse set of matters in the dangerous drugs arena, and last month was published by the Consumer Attorneys of California on litigation trends connected to Actos.

In this latest Canada-based study, researchers examined the records of over 115,000 patients treated with the Actos diabetes drug between 1988 and 2009. A review confirmed that taking Actos doubles the risk of bladder cancer. Actos is manufactured by Takeda Pharmaceuticals and is known generically as pioglitazone. In 2010, its annual sales reached almost $5 billion.

Both the United States and Europe issued warnings about the drug, but kept the drug on the market. Editorials have suggested this most recent study may prompt additional questions about Actos' use. 

Free Consultation

*indicates a required field